Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Keros Therapeutics, Inc. (KROS) is a Biotechnology company based in US with a market capitalization of $361.9M. Revenue grew 6775.0% year-over-year and the company generated $106M in free cash flow. This page tracks KROS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 163 employees · IPO Apr 8, 2020
Valuation
Valuation & price
$10.50as of May 17, 2026· -51.9% vs 52w high
4.6
P/E ratio
Latest-FY diluted EPS
1.19
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$361.9M
Market cap
6775.0%
Revenue growth (YoY)
99.4%
Gross margin
$106M
Free cash flow (USD)
-$270.5M
Net debt
Net cash position
-0.6%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2018 → 2025
Free cash flow by year
2018 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 14, 2026 (EPS $-1.21)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Keros Therapeutics, Inc.'s market cap?
Keros Therapeutics, Inc. (KROS) has a market capitalization of $361.9M.
What is KROS's P/E ratio?
KROS trades at a price-to-earnings ratio of 4.6, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is KROS's price-to-book (P/B) ratio?
KROS trades at 1.19 times book value per share.
When did Keros Therapeutics, Inc. last report earnings?
KROS last reported earnings on May 14, 2026; the next date is not yet scheduled.
Are insiders buying KROS stock?
SEC Form 4 filings show no open-market insider buys at Keros Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.